UWA-001

Not to be confused with UWA-101.
UWA-001
Systematic (IUPAC) name
2-(Benzo[d][1,3]dioxol-5-yl)-N-methyl-1-phenylethanamine
Chemical data
Formula C16H17NO2
Molar mass 255.31 g/mol

UWA-001 (also known as α-phenyl-MDMA and methylenedioxymephenidine) is a phenethylamine derivative invented at the University of Western Australia as non-toxic alternative to 3,4-methylenedioxy-N-methylamphetamine (MDMA) and researched as a potential treatment for Parkinson's disease.[1]

It has a 5-HT2A receptor affinity of 1.2 μM (∼10-fold increase compared to MDMA), 1.3 μM for the serotonin transporter (∼4-fold decrease compared to MDMA), 13.4 μM for the norepinephrine transporter (∼26-fold increase compared to MDMA) and virtually no affinity for the dopamine transporter (>50 μM).[1]

Unlike MDMA and para-methoxyamphetamine (but similarly to ketamine),[2] UWA-001 increases prepulse inhibition and was therefore considered to be non-psychoactive, though it was not assayed at other binding sites.[3] It is toxic to the SH-SY5Y cell line at high concentrations, however significantly less toxic than MDMA at all concentrations tested.[3]

UWA-001 is structurally related to the diarylethylamines lefetamine (a stimulant and opioid) and the dissociative anesthetic ephenidine, which acts as a NMDA receptor antagonist.

See also

References

  1. 1 2 Tom H. Johnston, Zak Millar, Philippe Huot, Keith Wagg‖, Sherri Thiele, Danielle Salomonczyk, Christopher J. Yong-Kee, Michael N. Gandy, Matthew McIldowie, Katie D. Lewis, Jordi Gomez-Ramirez, Joohyung Lee, Susan H. Fox, Mathew Martin-Iverson, Joanne E. Nash, Matthew J. Piggott, Jonathan M. Brotchie (May 2012). "A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances l-DOPA benefit in parkinsonian primates". The FASEB Journal 26 (5): 2154–2163. doi:10.1096/fj.11-195016. PMID 22345403.
  2. Kathryn M. Abel, Matthew P.G. Allin, David R Hemsley, Mark A. Geyer (May 2013). "Low dose ketamine increases prepulse inhibition in healthy men". Neuropharmacology 44 (6): 729–737. doi:10.1016/S0028-3908(03)00073-X. PMID 12681371.
  3. 1 2 Michael N. Gandy, Matthew McIldowie, Katie Lewis, Agata M. Wasik, Danielle Salomonczyk, Keith Wagg, Zak A. Millar, David Tindiglia, Philippe Huot, Tom Johnston, Sherri Thiele, Blake Nguyen, Nicholas M. Barnes, Jonathan M. Brotchie, Mathew T. Martin-Iverson, Joanne Nash, John Gordon, Matthew J. Piggott (2010). "Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity". Medicinal Chemical Communications 1: 287–293. doi:10.1039/C0MD00108B.


This article is issued from Wikipedia - version of the Tuesday, February 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.